Metered Dose Inhaler Devices Market Expected to Witness Massive Growth with a Tremendous CAGR of 3.99%, asserts DelveInsight

Metered Dose Inhaler Devices Market Expected to Witness Massive Growth with a Tremendous CAGR of 3.99%, asserts DelveInsight

“Metered Dose Inhaler Devices Market”
The global metered dose inhaler devices market was valued at USD 16,613 million in 2021, growing at a CAGR of 3.99% during the forecast period from 2022 to 2027 to reach USD 21,423 million by 2027.

The global metered dose inhaler devices market was valued at USD 16,613 million in 2021, growing at a CAGR of 3.99% during the forecast period from 2022 to 2027 to reach USD 21,423 million by 2027. 

The metered dose inhaler devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings. Therefore, the metered dose inhaler devices market is estimated to grow during the forecast period from 2022 to 2027.

Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd (LON: BXP), BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca (AZN:NASDAQ), Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.

DelveInsight’s “Metered Dose Inhaler Devices Market Insight & Forecast” report will offer an in-depth understanding of the Metered Dose Inhaler Devices market, further benefiting the competitors or stakeholders operating in the Metered Dose Inhaler Devices arena.

Metered Dose Inhaler Devices Overview

The Metered Dose Inhaler device (MDI) is a medication canister that is pressurised and held in a plastic container with a mouthpiece. When sprayed, it delivers a constant and predictable amount of medicine. It is the most widely utilized delivery method for treating asthma, COPD, and other respiratory illnesses.

Interested to know more about the functioning of Metered Dose Inhaler Devices- Visit @ Metered Dose Inhaler Devices Operations & Working.

Metered Dose Inhaler Devices Market Insights

Among all the regions, North America is expected to dominate the global metered dose inhaler devices market in the year 2021 and is expected to do the same during the forecast period from 2022-2027. Factors such as the rising prevalence of asthma and surge in cystic fibrosis cases are expected to increase the demand for metered dose inhaler devices in the North American market.

According to the data published by WHO from 3 January 2020 to 21 September 2022, there have been 94,471,064 confirmed cases of COVID-19 in United States. Further, COVID-19 increases the risk of respiratory infections in the patients affecting the lungs. Thus, rising prevalence of COVID increases the demand for metered dose inhaler devices, which surges the growth for metered dose inhaler devices overall market forecast.

Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per the cystic fibrosis Canada’s 2020 annual data report from the Canadian Cystic Fibrosis Registry, released that in 2020, there were 4,332 Canadians with CF, with 62% of them being adults. Further, metered dose inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for metered dose inhaler devices, which boost the metered dose inhaler devices overall market growth.

Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in metered dose inhaler devices market.

To read more about why North America is leading the market growth in the Metered Dose Inhaler Devices market, get a snapshot of the Metered Dose Inhaler Devices market report.

Metered Dose Inhaler Devices Market Dynamics

The increased prevalence of diabetes is one of the key factors driving the market for metered dose inhaler devices. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2021, worldwide, diabetes had affected about 537 million people of age between 20-79 years. Moreover, diabetes can be predicted to affect 643 million people worldwide by 2030 and 783 million people by 2045. Further, insulin powder is administered by metered dose inhalers to treat diabetes. As a result, the demand for metered dose inhaler devices rises due to an increase in diabetes cases, propelling the global metered dose inhaler devices market ahead over the forecast period (2022-2027).

Moreover, another key factor which is responsible for the growth of metered dose inhaler devices market is the increasing prevalence of asthma. For instance, according to the data published by World Health Organization (WHO) in the year 2022, in 2019, asthma afflicted an estimated 262 million individuals globally. Moreover, as per the data published by Asthma and Allergy Foundation of America in the year 2022, in 2019, approximately 25 million people had asthma in the United States. Thus, metered dose inhaler devices are used to treat asthma. Therefore, rising prevalence in asthma increases the demand for metered dose inhaler devices, which drives the overall metered dose inhaler devices market forward over the forecast period (2022-2027).

However, lack of awareness about metered dose inhaler devices and severe side effects associated with the devices, can hamper the global metered dose inhaler devices market growth.

The COVID-19 pandemic has positively impacted the market for metered dose inhaler devices, this can be due to the severe effects of COVID on lungs and it is estimated that people may have respiratory infections as an after effect of COVID, which surged the demand for metered dose inhaler devices among patients recovering with COVID, as well as shortness of breath as its prevalent symptom also contributed to the metered dose inhaler devices demand among COVID patients. Hence, the demand for metered dose inhaler devices will continue to rise in the forecast period from 2022-2027.

Recent Breakthroughs in Metered Dose Inhaler Devices Market:

  • In March 2022, Novartis’ Sandoz, a Swiss multinational pharmaceutical corporation, acquired, UK based delivery device development company, Coalesce Product Development Limited, developing a portfolio of inhalation devices. This includes new versions of pressurized metered dose inhalers (pMDI), breath-actuated inhalers (BAI) and pre-metered dry powder inhalers (DPI).
  • In February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a unique digital respiratory health solution that turns a normal metered dosage inhaler (pMDI) into a smart linked healthcare device.
  • In September 2021, BreatheSuite Inc., a Canadian connected respiratory health startup, announced that its BreatheSuite Metered-Dose Inhaler (MDI) V1 device has acquired 510(K) approval from the US Food and Drug Administration (FDA). The BreatheSuite gadget converts conventional MDIs into smart inhalers by automatically and objectively monitoring and delivering feedback on inhaler adherence and technique for persons with asthma and COPD. It is approved for both prescription and over-the-counter usage.

Key Players Proactively Working In the Metered Dose Inhaler Devices Market

Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.

Scope of the Metered Dose Inhaler Devices Market Report:

  • Geography Covered: Global
  • Forecast Period: 2022-2027
  • Key Metered Dose Inhaler Devices Companies: H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others
  • Market Segmentation by Patient Type: Adult And Pedriatric
  • Market Segmentation by Application: Chronic Obstructive Pulmonary Diseases (Copd), Asthma, Covid-19, Diabetes, And Others
  • Market Segmentation by Distribution Channel: Online And Offline
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Table of Contents 

1

Report Introduction

2

Executive Summary

3

Regulatory and Patent Analysis

4

Key Factors Analysis

5

Metered Dose Inhaler Devices Porter’s Five Forces Analysis

6

COVID-19 Impact Analysis on Metered Dose Inhaler Devices Market

7

Metered Dose Inhaler Devices Market Layout

8

Metered Dose Inhaler Devices Global Company Share Analysis – Key 3-5 Companies

9

Metered Dose Inhaler Devices Companies and Product Profiles

10

Project Approach

11

KOL Views

12

DelveInsight Capabilities

13

Disclaimer

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/